of likelihood of eventual transplant; or destination therapy (DT). Results: Recipients of CF LVADs (n 2775) had mean age 55 yrs, 79% male, prior CABG 22%. Strategy at implant was BTT 29% (n 796), BTC 42% (n 1162) (likely to be listed 69% (n 796), moderately likely 24% (n 282), unlikely 7% (n 84)), and DT 20% (n 553). DT patients had higher IM profiles at implant: IM profile 1, 2 and 3 for DT (6%, 39%, 55%), BTC (18%, 42%, 40%), and BTT (13%, 48%, 40%), p 0.0001. However DT patients were older and had more renal dysfunction, vascular disease, and lung disease. Overall survival (alive with LVAD or transplanted) was superior at 12 months for BTT v. BTC v. DT (86% v. 82% v. 78%, respectively, p 0.0002). The pre-implant assessment of the likelihood of transplant correlated with outcomes, figure 1a. Within a year of the approval of CF LVADs as DT, 35% of all CF LVADs were DT, whereas only 21% are BTT figure1b.